Literature DB >> 31106816

Sex-Related Effect on Immunotherapy Response: Implications and Opportunities.

Leandro Machado Colli1, Lindsay M Morton1, Stephen J Chanock1.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 31106816      PMCID： PMC6695311          DOI： 10.1093/jnci/djz096

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  12 in total

1.  The prognostic significance of tumor-infiltrating lymphocytes for primary melanoma varies by sex.

Authors:  Andrew J Sinnamon; Cimarron E Sharon; Yun Song; Madalyn G Neuwirth; David E Elder; Xiaowei Xu; Emily Y Chu; Michael E Ming; Douglas L Fraker; Phyllis A Gimotty; Giorgos C Karakousis
Journal:  J Am Acad Dermatol       Date:  2018-03-05       Impact factor: 11.527

Review 2.  Sex differences in immune responses.

Authors:  Sabra L Klein; Katie L Flanagan
Journal:  Nat Rev Immunol       Date:  2016-08-22       Impact factor: 53.106

3.  Sex-specific trends in lung cancer incidence and survival: a population study of 40,118 cases.

Authors:  Camilla M T Sagerup; Milada Småstuen; Tom B Johannesen; Åslaug Helland; Odd Terje Brustugun
Journal:  Thorax       Date:  2011-01-02       Impact factor: 9.139

Review 4.  Cancer immunotherapy comes of age.

Authors:  Ira Mellman; George Coukos; Glenn Dranoff
Journal:  Nature       Date:  2011-12-21       Impact factor: 49.962

5.  Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.

Authors:  Fabio Conforti; Laura Pala; Vincenzo Bagnardi; Tommaso De Pas; Marco Martinetti; Giuseppe Viale; Richard D Gelber; Aron Goldhirsch
Journal:  Lancet Oncol       Date:  2018-05-16       Impact factor: 41.316

6.  Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.

Authors:  Peter Schmid; Sylvia Adams; Hope S Rugo; Andreas Schneeweiss; Carlos H Barrios; Hiroji Iwata; Véronique Diéras; Roberto Hegg; Seock-Ah Im; Gail Shaw Wright; Volkmar Henschel; Luciana Molinero; Stephen Y Chui; Roel Funke; Amreen Husain; Eric P Winer; Sherene Loi; Leisha A Emens
Journal:  N Engl J Med       Date:  2018-10-20       Impact factor: 91.245

7.  Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis.

Authors:  Yucai Wang; Shouhao Zhou; Fang Yang; Xinyue Qi; Xin Wang; Xiaoxiang Guan; Chan Shen; Narjust Duma; Jesus Vera Aguilera; Ashish Chintakuntlawar; Katharine A Price; Julian R Molina; Lance C Pagliaro; Thorvardur R Halfdanarson; Axel Grothey; Svetomir N Markovic; Grzegorz S Nowakowski; Stephen M Ansell; Michael L Wang
Journal:  JAMA Oncol       Date:  2019-07-01       Impact factor: 31.777

8.  Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers: A Systematic Review and Meta-analysis.

Authors:  Christopher J D Wallis; Mohit Butaney; Raj Satkunasivam; Stephen J Freedland; Sandip P Patel; Omid Hamid; Sumanta K Pal; Zachary Klaassen
Journal:  JAMA Oncol       Date:  2019-04-01       Impact factor: 31.777

9.  Hypermutation of the inactive X chromosome is a frequent event in cancer.

Authors:  Natalie Jäger; Matthias Schlesner; David T W Jones; Simon Raffel; Jan-Philipp Mallm; Kristin M Junge; Dieter Weichenhan; Tobias Bauer; Naveed Ishaque; Marcel Kool; Paul A Northcott; Andrey Korshunov; Ruben M Drews; Jan Koster; Rogier Versteeg; Julia Richter; Michael Hummel; Stephen C Mack; Michael D Taylor; Hendrik Witt; Benedict Swartman; Dietrich Schulte-Bockholt; Marc Sultan; Marie-Laure Yaspo; Hans Lehrach; Barbara Hutter; Benedikt Brors; Stephan Wolf; Christoph Plass; Reiner Siebert; Andreas Trumpp; Karsten Rippe; Irina Lehmann; Peter Lichter; Stefan M Pfister; Roland Eils
Journal:  Cell       Date:  2013-10-17       Impact factor: 41.582

10.  Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs.

Authors:  Alyson Haslam; Vinay Prasad
Journal:  JAMA Netw Open       Date:  2019-05-03
View more
  1 in total

1.  Evaluating Treatment Tolerability in Cancer Clinical Trials Using the Toxicity Index.

Authors:  Gillian Gresham; Márcio A Diniz; Zahra S Razaee; Michael Luu; Sungjin Kim; Ron D Hays; Steven Piantadosi; Mourad Tighiouart; Greg Yothers; Patricia A Ganz; André Rogatko
Journal:  J Natl Cancer Inst       Date:  2020-12-14       Impact factor: 13.506
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.